PMID- 24013981
OWN - NLM
STAT- MEDLINE
DCOM- 20160805
LR  - 20221207
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 20
IP  - 2
DP  - 2014 Feb
TI  - Diabetes duration and the efficacy and safety of insulin glargine versus 
      comparator treatment in patients with type 2 diabetes mellitus.
PG  - 120-8
LID - 10.4158/EP13075.OR [doi]
AB  - OBJECTIVE: To evaluate the effect of diabetes duration on efficacy and safety in 
      patients with type 2 diabetes mellitus (T2DM) using insulin glargine versus 
      comparator (oral antidiabetic drugs [OADs], dietary changes, or other insulins). 
      METHODS: Data were pooled from randomized controlled clinical trials conducted in 
      adults with T2DM with at least 24-week treatment with insulin glargine or a 
      comparator, where predefined insulin titration algorithms were utilized to 
      achieve fasting plasma glucose (FPG) concentrations of </=100 mg/dL. Glycated 
      hemoglobin A1C (A1C), FPG, and insulin dose and safety (hypoglycemia) outcomes 
      were analyzed. RESULTS: Nine studies were included in the analysis of 2,930 
      patients. Patients with shorter duration of diabetes were more likely to have 
      greater reductions in A1C compared with those who had longer-duration disease 
      (P<.0001). Disease duration did not affect change in FPG concentrations (P = 
      .9017), but lower weight-adjusted insulin dose was correlated with 
      longer-duration disease (P<.0001). Patients with longer-duration diabetes had 
      increased risks of symptomatic hypoglycemia, confirmed hypoglycemia 
      (self-monitored blood glucose <50 mg/dL and <70 mg/dL), and nocturnal 
      hypoglycemia (all P<.001). No significant relationship was found between severe 
      hypoglycemia and duration of diabetes. However, treatment with insulin glargine 
      lowered A1C values more effectively than comparator treatments with fewer 
      hypoglycemic episodes. CONCLUSION: Patients with shorter-duration T2DM better 
      achieved target A1C levels and had less hypoglycemia than those with longer 
      disease duration. Insulin glargine was associated with reduced A1C and fewer 
      hypoglycemic events than comparators, regardless of disease duration.
FAU - Garg, Satish K
AU  - Garg SK
AD  - University of Colorado Denver, Aurora, Colorado.
FAU - Aurand, Lisa A
AU  - Aurand LA
AD  - Sanofi US, Inc., Bridgewater, New Jersey.
FAU - Rimler, Michael S
AU  - Rimler MS
AD  - Medpace, Cincinnati, Ohio.
FAU - Dailey, George E
AU  - Dailey GE
AD  - Scripps Clinic, La Jolla, California.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Glargine/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 2013/09/10 06:00
MHDA- 2016/08/06 06:00
CRDT- 2013/09/10 06:00
PHST- 2013/09/10 06:00 [entrez]
PHST- 2013/09/10 06:00 [pubmed]
PHST- 2016/08/06 06:00 [medline]
AID - S1530-891X(20)43738-3 [pii]
AID - 10.4158/EP13075.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2014 Feb;20(2):120-8. doi: 10.4158/EP13075.OR.